Guillaume Rémy advised Brainvectis’ shareholders in the context of the sale of the share capital of the company to the American corporation AskBio.

Created in 2015 by Pr. Nathalie Cartier, worldwide renowned gene therapy pioneer, Brainvectis is a company specialized in gene therapy of neurodegenerative diseases such as Huntington and Alzheimer.

In order to increase the metabolism of cholesterol  in the brain, the team, with support from INSERM, Sorbonne University and the French Alternative Energies and Atomic Energy Commission (CEA) has developed an innovative technology based on gene therapy to introduce an enzyme within the brain.

The integration of the Amercian group will enable the acceleration of the development of its therapy by Brainvectis.